{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.2%25+hypromellose+lubricant+eye+drops",
    "query": {
      "intervention": "0.2% hypromellose lubricant eye drops"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T14:32:08.374Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01525173",
      "title": "A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "0.1% brimonidine tartrate ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "0.01% bimatoprost ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "0.2% hypromellose lubricant eye drops",
          "type": "DRUG"
        },
        {
          "name": "latanoprost 0.005% ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 137,
      "start_date": "2012-01",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-07T14:32:08.374Z",
      "location_count": 1,
      "location_summary": "Deerfield Beach, Florida",
      "locations": [
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525173"
    },
    {
      "nct_id": "NCT01470118",
      "title": "A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Conjunctivitis, Allergic"
      ],
      "interventions": [
        {
          "name": "alcaftadine 0.25% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "olopatadine 0.2% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2011-10",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2013-02-21",
      "last_synced_at": "2026-10-07T14:32:08.374Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01470118"
    },
    {
      "nct_id": "NCT05660447",
      "title": "A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Rhegmatogenous Retinal Detachment",
        "Proliferative Vitreoretinopathy"
      ],
      "interventions": [
        {
          "name": "Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]",
          "type": "DRUG"
        },
        {
          "name": "Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2023-02-06",
      "completion_date": "2025-01-31",
      "has_results": false,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-10-07T14:32:08.374Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05660447"
    },
    {
      "nct_id": "NCT01170884",
      "title": "Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2009-12",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2019-04-24",
      "last_synced_at": "2026-10-07T14:32:08.374Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01170884"
    },
    {
      "nct_id": "NCT01495338",
      "title": "A Comparison of the Safety and Comfort of AC-170",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Ocular Health"
      ],
      "interventions": [
        {
          "name": "AC-170 0.17%",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0.24% (Formulation 1)",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0.24% (Formulation 2)",
          "type": "DRUG"
        },
        {
          "name": "Olopatadine hydrochloride 0.2%/Tears Naturale II",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aciex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2011-12",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2017-09-14",
      "last_synced_at": "2026-10-07T14:32:08.374Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495338"
    },
    {
      "nct_id": "NCT07413172",
      "title": "Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye",
        "Eye Diseases",
        "Eyes Dry Chronic"
      ],
      "interventions": [
        {
          "name": "Autologous Serum Tears (50% Autologous Serum Tears + 0.2% Sodium Hyaluronate)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biological - Autologous Serum Tears (50% Autologous Serum Tears + Balanced Saline Solution (BSS)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of Care (SOC) Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-07-21",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-07T14:32:08.374Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07413172"
    },
    {
      "nct_id": "NCT01732757",
      "title": "A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Conjunctivitis, Allergic"
      ],
      "interventions": [
        {
          "name": "Alcaftadine 0.25%",
          "type": "DRUG"
        },
        {
          "name": "Olopatadine 0.2%",
          "type": "DRUG"
        },
        {
          "name": "dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 157,
      "start_date": "2012-11",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-01-14",
      "last_synced_at": "2026-10-07T14:32:08.374Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01732757"
    },
    {
      "nct_id": "NCT00689078",
      "title": "Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Prednisolone Acetate 1%",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate 0.12%",
          "type": "DRUG"
        },
        {
          "name": "Loteprednol Etabonate 0.2%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ORA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2008-05",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-10-07T14:32:08.374Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00689078"
    },
    {
      "nct_id": "NCT00836485",
      "title": "Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Ketotifen 4.0% Patch",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Olopatadine 0.2%",
          "type": "DRUG"
        },
        {
          "name": "Artificial tears",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Senju USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2009-02",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2023-08-04",
      "last_synced_at": "2026-10-07T14:32:08.374Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00836485"
    }
  ]
}